PDF(Pubmed)
Abstract：
Angiogenesis is the formation of new blood vessel from existing vessels and is a critical first step in tissue repair following chronic disturbances in healing and degenerative tissues. Chronic pathoanatomic tissues are characterized by a high number of inflammatory cells; an overexpression of inflammatory mediators; such as tumor necrosis factor-α (TNF-α) and interleukin-1 (IL-1); the presence of mast cells, T cells, reactive oxygen species, and matrix metalloproteinases; and a decreased angiogenic capacity. Multiple studies have demonstrated that autologous orthobiological cellular preparations (e.g., platelet-rich plasma (PRP)) improve tissue repair and regenerate tissues. There are many PRP devices on the market. Unfortunately, they differ greatly in platelet numbers, cellular composition, and bioformulation. PRP is a platelet concentrate consisting of a high concentration of platelets, with or without certain leukocytes, platelet-derived growth factors (PGFs), cytokines, molecules, and signaling cells. Several PRP products have immunomodulatory capacities that can influence resident cells in a diseased microenvironment, inducing tissue repair or regeneration. Generally, PRP is a blood-derived product, regardless of its platelet number and bioformulation, and the literature indicates both positive and negative patient treatment outcomes. Strangely, the literature does not designate specific PRP preparation qualifications that can potentially contribute to tissue repair. Moreover, the literature scarcely addresses the impact of platelets and leukocytes in PRP on (neo)angiogenesis, other than a general one-size-fits-all statement that \"PRP has angiogenic capabilities\". Here, we review the cellular composition of all PRP constituents, including leukocytes, and describe the importance of platelet dosing and bioformulation strategies in orthobiological applications to initiate angiogenic pathways that re-establish microvasculature networks, facilitating the supply of oxygen and nutrients to impaired tissues.
摘要：
血管生成是从现有血管形成新血管,并且是在愈合和变性组织中的慢性紊乱之后的组织修复中的关键的第一步。慢性病理解剖组织的特征是大量的炎症细胞;炎症介质的过度表达;如肿瘤坏死因子-α（TNF-α）和白细胞介素-1（IL-1）;肥大细胞的存在，T细胞,活性氧，和基质金属蛋白酶；和降低的血管生成能力。多项研究表明，自体体态生物学细胞制剂(例如，富血小板血浆（PRP））改善组织修复和再生组织。市场上有许多PRP设备。不幸的是,它们的血小板数量差异很大，细胞组成，和生物制剂。PRP是一种由高浓度血小板组成的血小板浓缩物，有或没有某些白细胞，血小板衍生生长因子（PGFs），细胞因子,分子，和信号细胞。几种PRP产品具有免疫调节能力，可以影响患病微环境中的常驻细胞。诱导组织修复或再生。一般来说,PRP是一种血液衍生产品,不管它的血小板数量和生物制剂，文献显示患者治疗结果为阳性和阴性.奇怪的是,文献没有指定可能有助于组织修复的特定PRP制备资格.此外，文献很少讨论PRP中血小板和白细胞对（新）血管生成的影响，除了“PRP具有血管生成能力”的通用一刀切的声明之外。这里,我们回顾了所有PRP成分的细胞组成，包括白细胞,并描述了血小板给药和生物制剂策略在体态生物学应用中的重要性，以启动重新建立微血管网络的血管生成途径，促进氧气和营养向受损组织的供应。
